Identification of Copy Number Variation-Driven Molecular Subtypes in Pancreatic Adenocarcinoma of Chinese Cohort

Qian Zhan,Chenlei Wen,Yi Zhao,Lu Fang,Yangbing Jin,Zehui Zhang,Siyi Zou,Fanlu Li,Ying Yang,Lijia Wu,Jiabin Jin,Xiongxiong Lu,Junjie Xie,Dongfeng Cheng,Zhiwei Xu,Jun Zhang,Jiancheng Wang,Xiaxing Deng,Hao Chen,Chenghong Peng,Hongwei Li,Henghui Zhang,Hai Fang,Chao-Fu Wang,Baiyong Shen

DOI: https://doi.org/10.2139/ssrn.3839411

2021-01-01

Abstract:Pancreatic adenocarcinoma (PAAD) is one of the most lethal carcinomas all over the world. The current histopathological classifications for PAAD are of limited use to guide clinical decision-making, and there is an unmet need to identify new biomarkers for molecular subtyping. We profiled a comprehensive landscape of genomic alterations for 608 PAAD patients in a Chinese cohort, including somatic mutations, pathogenic germline variants and copy number variations (CNV). Our data provided no evidence of associations with prognosis based on the information of point mutations in either highly mutated genes (such as KRAS, TP53, CDKN2A and SMAD4) or homologous recombination repair genes. Instead, associated with worse prognosis were amplified genes involved in DNA repair and receptor tyrosine kinase related signaling pathways. Motivated by this observation, we categorized patients into four molecular subtypes (namely repair-deficient, proliferation-active, repair-proficient and repair-enhanced) that differed in prognosis. Together with the evidence from genomic footprint analysis, we suggested that repair-deficient and proliferation-active subtypes were better suited for DNA damage therapies, while immunotherapy was highly recommended for repair-proficient and repair-enhanced subtypes. Collectively, our findings represent a significant step in improving diagnosis and management for PAAD patients. Funding Statement: This work was supported by the National Natural Science Foundation of China (grant numbers 81470894, 81502695, 81672325, 81871906, 82073326) and the Shanghai Sailing Program (grant number 20YF1426900). Declaration of Interests: The authors declare no potential conflicts of interest. Ethics Approval Statement: The overall study protocol was approved by the Medical Ethical Committee of Ruijin Hospital and the research was conducted in accordance with relevant ethical guidelines.